# Lead4Life PPP 2026 – Lead-212 Radiopharmaceutical Development

**Funder:** KWF
**Budget:** €0.5M–€2M per project (total programme €5M)
**Deadline:** 22 September 2026 (12:00 noon; full-proposal phase opened 5 May 2026)
**Duration:** Up to 4 years
**Consortium:** Required — public-private partnership consortium; Consortium Agreement between all participants is mandatory
**Application:** 2-stage: matchmaking phase → full-proposal submission via KWF GMS
**TRL:** 1-7
**Frequency:** One-off
**Eligible countries:** NL
**Official call:** https://www.kwf.nl/en/forresearchers/funding/lead4life
**Last verified:** 21 June 2026

## Eligibility & scope

Health~Holland PPP call for projects on lead-212 production/supply chain or enabling technologies for clinical introduction of Pb-212 radiopharmaceuticals. Proposals must include a private party (not in financial difficulty) and comply with Health~Holland PPP requirements. Consortium Agreement required; applicants must register in KWF GMS at least 6 weeks before closing. Dutch Summary reviewed by Patient Advisory Committee (PACO).

## Summary

The KWF Lead4Life PPP 2026 call funds public-private partnerships to develop lead-212 production, supply chains, and enabling technologies for clinical radiopharmaceutical applications, with budgets from €500,000 to €2 million per project. Consortia must include at least one private-sector partner and span technology readiness levels 1-7. This is a one-off call aligned with Health~Holland PPP requirements, open to Dutch research institutions and industry partners.

## Who should apply

- Research institutions and clinical centres in the Netherlands with radiopharmaceutical expertise
- Private-sector partners (pharma, medical-device, supply-chain companies) with track record and financial stability
- Consortia addressing lead-212 production, purification, or clinical translation
- Teams prepared to commit 3-4 years to TRL advancement
- Institutions not yet in KWF GMS should register at least 6 weeks before the 22 September deadline

## Key dates

- Full-proposal deadline: 22 September 2026 at 12:00 noon CET
- Two-stage process: matchmaking phase precedes full proposal submission
- Project duration: up to 4 years

## Tips for applicants

- Private-sector partner selection is gating, ensure your industry partner is solvent and has a credible interest in the technology; KWF screens for financial difficulty.
- A Dutch-language summary for the Patient Advisory Committee is mandatory; invest in clear, non-technical language, as this summary shapes perceived public benefit.
- Attend or engage the matchmaking phase actively; consortium chemistry and roles are decisive before full-proposal writing.

## Frequently asked questions

### What is the budget range for the KWF Lead4Life PPP 2026?

€500,000 to €2 million per project, with a total programme budget of €5 million.

### Who must be part of a Lead4Life PPP consortium?

At minimum, a public research institution or clinical centre and a private-sector partner in good financial standing; consortia must have a signed Consortium Agreement.

### Is this a recurring call?

No, Lead4Life PPP 2026 is a one-off call aligned with the Health~Holland PPP framework.

### What is the deadline for Lead4Life PPP 2026?

Full-proposal deadline is 22 September 2026 at 12:00 noon CET, preceded by a matchmaking phase.

### Do I need to register in KWF GMS before applying?

If your institution is not yet registered, you must complete registration at least 6 weeks before the 22 September deadline.

---

Source: [The Great Grantsby](https://grantsby.eu/grants/kwf-lead4life-ppp-2026-lead-212-radiopharmaceutical-de) — EU grant monitoring for academic researchers. Always verify details on the funder's website before applying.